Linafexor Drug Asset Due Diligence Report 2026

This Linafexor Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Linafexor can convert its Small molecule drug profile and FXR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Linafexor (query alias: Linafexor)
Modality / target	Small molecule drug; FXR; FXR agonists
Highest global status	Phase 3
Originator	Cascade Pharmaceuticals, Inc.
Active developers	Cascade Pharmaceuticals, Inc.

The MCP disease footprint includes Primary Biliary Cholangitis, Cholangitis, Sclerosing, Metabolic Dysfunction Associated Steatohepatitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07282353	Phase 3	Recruiting	135	The proportion of patients who achieve the composite response criteria at Week 52
NCT07429331	Phase 1	Completed	32	Cmax of CS0159
NCT06888115	Phase 1	Completed	24	Pharmacokinetic parameters of CS0159 (Cmax)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Linafexor addresses Primary Biliary Cholangitis, Cholangitis, Sclerosing, Metabolic Dysfunction Associated Steatohepatitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 17 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: FXR records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-04-15	Norgine completes acquisition of Theravia	Approved	Financial terms not disclosed
2025-02-25	Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company	Phase 2/3	Financial terms not disclosed
2023-09-26	Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	Approved	US$713.1M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Preparation and application of novel FXR small-molecule agonist”. The milestone feed surfaced a patent-application signal described as “Preparation and application of novel FXR small-molecule agonist”. The milestone feed surfaced a patent-application signal described as “Preparation and application of novel FXR small-molecule agonist”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION